United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 5 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trial

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine 15 mg - mirtazapine tablets are indicated for the treatment of major depressive disorder.   the efficacy of mirtazapine tablets in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders – 3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology ).  a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation.  the effectiveness of mirtazapine tablets in

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - levothyroxine (unii: q51bo43mg4) (levothyroxine - unii:q51bo43mg4), liothyronine (unii: 06lu7c9h1v) (liothyronine - unii:06lu7c9h1v) - levothyroxine 38 ug - indications and usage: np thyroid tablets (thyroid tablets, usp) are indicated: 1. as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (see warnings). 2. as pituitary tsh suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic iymphocytic thyroiditis (hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. as diagnostic agents in suppression tests to differentiate su

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - levothyroxine (unii: q51bo43mg4) (levothyroxine - unii:q51bo43mg4), liothyronine (unii: 06lu7c9h1v) (liothyronine - unii:06lu7c9h1v) - levothyroxine 19 ug - indications and usage: np thyroid tablets (thyroid tablets, usp) are indicated: 1. as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (see warnings). 2. as pituitary tsh suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic iymphocytic thyroiditis (hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. as diagnostic agents in suppression tests to differentiate su

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - levothyroxine (unii: q51bo43mg4) (levothyroxine - unii:q51bo43mg4), liothyronine (unii: 06lu7c9h1v) (liothyronine - unii:06lu7c9h1v) - levothyroxine 76 ug - indications and usage: np thyroid tablets (thyroid tablets, usp) are indicated: 1. as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (see warnings). 2. as pituitary tsh suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic iymphocytic thyroiditis (hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. as diagnostic agents in suppression tests to differentiate su

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - levothyroxine (unii: q51bo43mg4) (levothyroxine - unii:q51bo43mg4), liothyronine (unii: 06lu7c9h1v) (liothyronine - unii:06lu7c9h1v) - levothyroxine 57 ug - indications and usage: np thyroid tablets (thyroid tablets, usp) are indicated: 1. as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (see warnings). 2. as pituitary tsh suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic iymphocytic thyroiditis (hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. as diagnostic agents in suppression tests to differentiate su

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 10 mg - paroxetine tablets, usp are indicated for the treatment of major depressive disorder.  the efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation.  the effects of paroxetine in hospitalized depressed patients have not been adequately studied.  the efficacy of paroxetine in m

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - lisinopril 10 mg - lisinopril and hydrochlorothiazide tablets usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - lovastatin (unii: 9lhu78oqfd) (lovastatin - unii:9lhu78oqfd) - lovastatin 20 mg - therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-c and ldl-c to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. in individuals without symptomatic cardiovascular disease, average to moderately elevated total-c and ldl-c, and below average hdl-c, lovastatin is indicated to reduce the risk of: (see clinical pharmacology, clinical studies .) lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-c and ldl-c to target levels. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. lovastatin is indicated as an adjunct to diet for the reduction of elevated total-c and ldl-c levels in patients with primary hypercholesterolemia (types iia and iib 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. lovastatin is indicated as an adjunct to diet to reduce total-c, ldl-c and apolipoprotein b levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with hefh if after an adequate trial of diet therapy the following findings are present: prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-c, hdl-c, and tg. for patients with tg less than 400 mg/dl (<4.5 mmol/l), ldl-c can be estimated using the following equation: ldl-c = total-c - [0.2 × (tg) + hdl-c] for tg levels >400 mg/dl (>4.5 mmol/l), this equation is less accurate and ldl-c concentrations should be determined by ultracentrifugation. in hypertriglyceridemic patients, ldl-c may be low or normal despite elevated total-c. in such cases, lovastatin is not indicated. the national cholesterol education program (ncep) treatment guidelines are summarized below: ncep treatment guidelines: ldl-c goals and cutpoints for therapeutic lifestyle changes and drug therapy in different risk categories risk category ldl goal (mg/dl) ldl level at which to initiate therapeutic lifestyle changes (mg/dl) ldl level at which to consider drug therapy (mg/dl) chd † or chd risk equivalents (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) †† 2+ risk factors (10 year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk <10%: ≥160 0-1 risk factor ††† <160 ≥160 ≥190 (160-189: ldl-lowering drug optional) lipid elevations type lipoproteins elevated major minor i chylomicrons tg ↑→c iia ldl c -- iib ldl, vldl c tg iii (rare) idl c/tg -- iv vldl tg ↑→c v (rare) chylomicrons, vldl tg ↑→c idl = intermediate-density lipoprotein. after the ldl-c goal has been achieved, if the tg is still ≥200 mg/dl, non-hdl-c (total-c minus hdl-c) becomes a secondary target of therapy. non-hdl-c goals are set 30 mg/dl higher than ldl-c goals for each risk category. at the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the ldl-c is ≥130 mg/dl (see ncep guidelines above). since the goal of treatment is to lower ldl-c, the ncep recommends that ldl-c levels be used to initiate and assess treatment response. only if ldl-c levels are not available, should the total-c be used to monitor therapy. although lovastatin may be useful to reduce elevated ldl-c levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (type iib hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, vldl or idl (i.e., hyperlipoproteinemia types i, iii, iv, or v). *** the ncep classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: category total-c (mg/dl) ldl-c (mg/dl) acceptable <170 <110 borderline 170-199 110-129 high ≥200 ≥130 children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for ldl-c. hypersensitivity to any component of this medication. active liver disease or unexplained persistent elevations of serum transaminases (see warnings ). concomitant administration with strong cyp3a4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, hiv protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin ,nefazodone, and cobicistat-containing products) (see warnings, myopathy/rhabdomyolysis) . pregnancy and lactation. ( see precautions, pregnancy and nursing mothers).    atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. because of the ability of inhibitors of hmg-coa reductase such as lovastatin to decrease the synthesis of cholesterol and possibly other products of the cholesterol biosynthesis pathway, lovastatin is contraindicated during pregnancy and in nursing mothers. lovastatin should be administered to women of childbearing age only when such patients are highly unlikely to conceive. if the patient becomes pregnant while taking this drug, lovastatin should be discontinued immediately and the patient should be apprised of the potential hazard to the fetus (see precautions, pregnancy ).

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium is used for the following indications: hypothyroidism - as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. pituitary tsh suppression - in the treatment or prevention of various types of euthyroid goiters (see warnings and precautions ), including thyroid nodules (see warnings and precautions ), subacute or chronic iymphocytic thyroiditis (hashimoto's thyroiditis), multinodular goiter (see warnings and precautions ), and, as an adjunct to surgery and radioiodine therapy in the managem